CoChat
Sign Up
Cited by 216Neuroinflammation and Neurodegeneration MechanismsGlycosylation and Glycoproteins ResearchInflammasome and immune disorders

The Role of GPNMB in Inflammation

Open access
Saade, Marina, Araujo de Souza, Giovanna, Scavone, Cristoforo, Kinoshita, Paula Fernanda·2021·Frontiers in Immunology
DOI 10.3389/fimmu.2021.674739PMC PMC8149902
Open this paper in CoChat — free accountOpen PDF

Abstract

Inflammation is a response to a lesion in the tissue or infection. This process occurs in a specific manner in the central nervous system and is called neuroinflammation, which is involved in neurodegenerative diseases. GPNMB, an endogenous glycoprotein, has been recently related to inflammation and neuroinflammation. GPNMB is highly expressed in macrophages and microglia, which are cells involved with innate immune response in the periphery and the brain, respectively. Some studies have shown increased levels of GPNMB in pro-inflammatory conditions, such as LPS treatment, and in pathological conditions, such as neurodegenerative diseases and cancer. However, the role of GPNMB in inflammation is still not clear. Even though most studies suggest that GPNMB might have an anti-inflammatory role by promoting inflammation resolution, there is evidence that GPNMB could be pro-inflammatory. In this review, we gather and discuss the published evidence regarding this interaction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.674739

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GPNMB is a transmembrane glycoprotein that has been studied before in cancer and inflammation.

    “GPNMB (Glycoprotein nonmetastatic melanoma protein B) is a transmembrane glycoprotein, which has been studied before in cancer and inflammation (Saade et al, 2021).”

    From The genetic regulation of protein expression in cerebrospinal fluid (2023) · cites this paper as Saade et al, 2021

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. [2]Barton GM. A Calculated Response: Control of Inflammation by the Innate Immune System. J Clin Invest (2008) 118(2): 413–20. 10.1172/JCI34431 PMC2214713 18246191 · DOI · Paper page
  2. [3]Nathan C. Points of Control in Inflammation. Nature (2002) 420(6917): 846–52. 10.1038/nature01320 12490957 · DOI · Paper page
  3. [5]Mills CD. M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol (2012) 32(6): 463–88. 10.1615/CritRevImmunol.v32.i6.10 23428224 · DOI
  4. [6]Fleetwood AJ Lawrence T Hamilton JA Cook AD. Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage Csf-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation. J Immunol (2007) 178(8): 5245–52. 10.4049/jimmunol.178.8.5245 17404308 · DOI · Paper page
  5. [7]Italiani P Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol (2014) 5: 514. 10.3389/fimmu.2014.00514 25368618 PMC4201108 · DOI · Paper page
  6. [8]Cronkite DA Strutt TM. The Regulation of Inflammation by Innate and Adaptive Lymphocytes. J Immunol Res (2018) 2018: 1– 14. 10.1155/2018/1467538 PMC6016164 29992170 · DOI
  7. [13]Glass CK Saijo K Winner B Marchetto MC Gage FH. Mechanisms Underlying Inflammation in Neurodegeneration. Cell (2010) 140(6): 918–34. 10.1016/j.cell.2010.02.016 PMC2873093 20303880 · DOI · Paper page
  8. [14]Bachiller S Jiménez-Ferrer I Paulus A Yang Y Swanberg M Deierborg T. Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. Front Cell Neurosci (2018) 12: 488. 10.3389/fncel.2018.00488 30618635 PMC6305407 · DOI
  9. [15]Shemer A Erny D Jung S Prinz M. Microglia Plasticity During Health and Disease: An Immunological Perspective. Trends Immunol (2015) 36: 614–24. 10.1016/j.it.2015.08.003 26431939 · DOI · Paper page
  10. [16]Hu X Leak RK Shi Y Suenaga J Gao Y Zheng P. Microglial and Macrophage Polarization - New Prospects for Brain Repair. Nat Rev Neurol (2015) 11: 56– 64. 10.1038/nrneurol.2014.207 25385337 PMC4395497 · DOI
  11. [17]Tang Y Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol (2016) 53(2): 1181–94. 10.1007/s12035-014-9070-5 25598354 · DOI · Paper page
  12. [18]Li Q Barres BA. Microglia and Macrophages in Brain Homeostasis and Disease. Nat Rev Immunol (2018) 18(4): 225–42. 10.1038/nri.2017.125 29151590 · DOI · Paper page
  13. [19]Merson TD Binder MD Kilpatrick TJ. Role of Cytokines as Mediators and Regulators of Microglial Activity in Inflammatory Demyelination of the CNS. Neuromol Med (2010) 12(2): 99– 132. 10.1007/s12017-010-8112-z 20411441 · DOI
  14. [22]Weterman MA Ajubi N van Dinter IM Degen WG van Muijen GN Ruitter DJ. Nmb, a Novel Gene, is Expressed in Low-Metastatic Human Melanoma Cell Lines and Xenografts. Int J Cancer (1995) 60(1): 73– 81. 10.1002/ijc.2910600111 7814155 · DOI
  15. [24]Taya M Hammes SR. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target. Steroids (2018) 133: 102–7. 10.1016/j.steroids.2017.10.013 PMC6166407 29097143 · DOI
  16. [25]van der Lienden MJC Gaspar P Boot R Aerts J van Eijk M. Glycoprotein non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages. Int J Mol Sci (2018) 20(1): 66. 10.3390/ijms20010066 PMC6337583 30586924 · DOI · Paper page
  17. [26]Abdelmagid SM Barbe MF Rico MC Salihoglu S Arango-hisijara I Selim AH. Osteoactivin, an Anabolic Factor That Regulates Osteoblast Differentiation and Function. Exp Cell Res (2008) 314(13): 2334–51. 10.1016/j.yexcr.2008.02.006 18555216 · DOI
  18. [27]Rose AA Annis MG Dong Z Pepin F Hallett M Park M. ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain With Angiogenic Properties. PloS One (2010) 5(8): e12093. 10.1371/journal.pone.0012093 20711474 PMC2919417 · DOI
  19. [28]Furochi H Tamura S Mameoka M Yamada C Ogawa T Hirasaka K. Osteoactivin Fragments Produced by Ectodomain Shedding Induce MMP-3 Expression Via ERK Pathway in Mouse NIH-3T3 Fibroblasts. FEBS Lett (2007) 581(30): 5743–50. 10.1016/j.febslet.2007.11.036 18036345 · DOI
  20. [29]Bandari PS Qian J Yehia G Joshi DD Maloof PB Potian J. Hematopoietic Growth Factor Inducible Neurokinin-1 Type: A Transmembrane Protein That is Similar to Neurokinin 1 Interacts With Substance P. Regul Pept (2003) 111(1–3): 169–78. 10.1016/S0167-0115(02)00288-4 12609765 · DOI
  21. [30]Chung JS Sato K Dougherty II Cruz PD Jr Ariizumi K. Dc-HIL is a Negative Regulator of T Lymphocyte Activation. Blood (2007a) 109(10): 4320–7. 10.1182/blood-2006-11-053769 PMC1885497 17284525 · DOI
  22. [31]Shikano S Bonkobara M Zukas PK Ariizumi K. Molecular Cloning of a Dendritic Cell-Associated Transmembrane Protein, DC-HIL, That Promotes RGD-dependent Adhesion of Endothelial Cells Through Recognition of Heparan Sulfate Proteoglycans. J Biol Chem (2001) 276(11): 8125–34. 10.1074/jbc.M008539200 11114299 · DOI
  23. [32]Maric G Rose AA Annis MG Siegel PM. Glycoprotein non-Metastatic B (Gpnmb): A Metastatic Mediator and Emerging Therapeutic Target in Cancer. Onco Targets Ther (2013) 9(6): 839–52. 10.2147/OTT.S44906 PMC3711880 23874106 · DOI
  24. [33]Tanaka H Shimazawa M Kimura M Takata M Tsuruma K Yamada M. The Potential of GPNMB as Novel Neuroprotective Factor in Amyotrophic Lateral Sclerosis. Sci Rep (2012) 2: 573. 10.1038/srep00573 22891158 PMC3417778 · DOI
  25. [34]Ono Y Tsuruma K Takata M Shimazawa M Hara H. Glycoprotein Nonmetastatic Melanoma Protein B Extracellular Fragment Shows Neuroprotective Effects and Activates the PI3K/Akt and MEK/ERK Pathways Via the Na +/K +-Atpase. Sci Rep (2016) 6(1): 23241. 10.1038/srep23241 26988030 PMC4796790 · DOI
  26. [35]Bai D Ueno L Vogt PK. Akt-Mediated Regulation of Nfκb and the Essentialness of Nfκb for the Oncogenicity of PI3K and Akt. Int J Cancer (2009) 125(12): 2863–70. 10.1002/ijc.24748 PMC2767458 19609947 · DOI · Paper page
  27. [36]Maeng YS Min JK Kim JH Yamagishi A Mochizuki N Kwon JY. ERK is an Anti-Inflammatory Signal That Suppresses Expression of NF-kappaB-dependent Inflammatory Genes by Inhibiting IKK Activity in Endothelial Cells. Cell Signal (2006) 18(7): 994– 1005. 10.1016/j.cellsig.2005.08.007 16242916 · DOI
  28. [37]Nakano Y Suzuki Y Takagi T Kitashoji A Ono Y Tsuruma K. Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) as a Novel Neuroprotective Factor in Cerebral Ischemia-Reperfusion Injury. Neuroscience (2014) 277: 123–31. 10.1016/j.neuroscience.2014.06.065 25010402 · DOI
  29. [38]Yu B Sondag GR Malcuit C Kim MH Safadi FF. Macrophage-Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration Via a CD44-Dependent Mechanism. J Cell Biochem (2016) 117(7): 1511–21. 10.1002/jcb.25394 26442636 · DOI
  30. [39]Linton MF Moslehi JJ Babaev VR. Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis. Int J Mol Sci (2019) 20(11): 2703. 10.3390/ijms20112703 PMC6600269 31159424 · DOI
  31. [40]Tomihari M Chung JS Akiyoshi H Cruz PD Jr Ariizumi K. DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells. Cancer Res (2010) 70(14): 5778–87. 10.1158/0008-5472.CAN-09-2538 PMC2905472 20570888 · DOI
  32. [41]Bao G Wang N Li R Xu G Liu P He B. Glycoprotein non-Metastatic Melanoma Protein B Promotes Glioma Motility and Angiogenesis Through the Wnt/β-Catenin Signaling Pathway. Exp Biol Med (2016) 241(17): 1968–76. 10.1177/1535370216654224 PMC5068464 27334625 · DOI
  33. [42]Rose AA Siegel PM. Osteoactivin/HGFIN: Is it a Tumor Suppressor or Mediator of Metastasis in Breast Cancer? Breast Cancer Res (2007) 9(6): 403. 10.1186/bcr1791 18086324 PMC2246174 · DOI
  34. [43]Ren F Zhao Q Liu B Sun X Tang Y Huang H. Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer. J Cell Physiol (2020) 235(3): 2738–52. 10.1002/jcp.29177 31498430 · DOI
  35. [45]Chung JS Bonkobara M Tomihari M Cruz PD Jr Ariizumi K. The DC-HIL/syndecan-4 Pathway Inhibits Human Allogeneic T-cell Responses. Eur J Immunol (2009) 39(4): 965–74. 10.1002/eji.200838990 PMC2766302 19350579 · DOI
  36. [46]Ott PA Hamid O Pavlick AC Kluger H Kim KB Boasberg PD. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. J Clin Oncol (2014) 32(32): 3659–66. 10.1200/JCO.2013.54.8115 PMC4879709 25267741 · DOI
  37. [47]Bendell J Saleh M Rose AAN Siegel PM Hart L Sirpal S. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. J Clin Oncol (2014) 32(32): 3619–25. 10.1200/JCO.2013.52.5683 25267761 · DOI
  38. [48]Yardley DA Weaver R Melisko ME Saleh MN Arena FP Forero A. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-expressing Breast Cancer. J Clin Oncol (2015) 33(14): 1609–19. 10.1200/JCO.2014.56.2959 25847941 · DOI
  39. [50]Huang JJ Ma WJ Yokoyama S. Expression and Immunolocalization of Gpnmb, a Glioma-Associated Glycoprotein, in Normal and Inflamed Central Nervous Systems of Adult Rats. Brain Behav (2012) 2(2): 85– 96. 10.1002/brb3.39 22574278 PMC3345354 · DOI
  40. [51]Shi F Duan S Cui J Yan X Li H Wang Y. Induction of Matrix Metalloproteinase-3 (Mmp-3) Expression in the Microglia by Lipopolysaccharide (LPS) Via Upregulation of Glycoprotein Nonmetastatic Melanoma B (Gpnmb) Expression. J Mol Neurosci (2014) 54(2): 234–42. 10.1007/s12031-014-0280-0 24682924 · DOI
  41. [52]Ripoll VM Irvine KM Ravasi T Sweet MJ Hume DA. Gpnmb is Induced in Macrophages by IFN-gamma and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses. J Immunol (2007) 178(10): 6557–66. 10.4049/jimmunol.178.10.6557 17475886 · DOI
  42. [53]Moloney EB Moskites A Ferrari EJ Isacson I Hallett PJ. The Glycoprotein GPNMB is Selectively Elevated in the Substantia Nigra of Parkinson’s Disease Patients and Increases After Lysosomal Stress. Neurobiol Dis (2018) 120: 1– 11. 10.1016/j.nbd.2018.08.013 30149180 PMC6748034 · DOI
  43. [54]Neal ML Boyle AM Budge KM Safadi FF Richardson R. The Glycoprotein GPNMB Attenuates Astrocyte Inflammatory Responses Through the CD44 Receptor. J Neuroinflammation (2018) 15(1): 73. 10.1186/s12974-018-1100-1 29519253 PMC5842560 · DOI
  44. [55]Michalinos A Tsaroucha AK Lambropoulou M Schizas D Valsami G Kostomitsopoulos N. Glycoprotein non-Metastatic Melanoma B Expression After Hepatic Ischemia Reperfusion and the Effect of Silibinin. Transl Gastroenterol Hepatol (2020) 5: 7. 10.21037/tgh.2019.11.01 32190775 PMC7061179 · DOI
  45. [56]Zhou L Zhuo H Ouyang H Liu Y Yuan F Sun L. Glycoprotein non-Metastatic Melanoma Protein B (Gpnmb) is Highly Expressed in Macrophages of Acute Injured Kidney and Promotes M2 Macrophages Polarization. Cell Immunol (2017) 316: 53– 60. 10.1016/j.cellimm.2017.03.006 28433199 · DOI
  46. [57]Haralanova-Ilieva B Ramadori G Armbrust T. Expression of Osteoactivin in Rat and Human Liver and Isolated Rat Liver Cells. J Hepatol (2005) 42(4): 565–72. 10.1016/j.jhep.2004.12.021 15763343 · DOI
  47. [58]Pahl MV Vaziri ND Yuan J Adler SG. Upregulation of Monocyte/Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal Disease. Clin J Am Soc Nephrol (2010) 5(1): 56– 61. 10.2215/CJN.03390509 19833906 PMC2801651 · DOI
  48. [59]Marques ARA Gabriel TL Aten J van Roomen CPAA Ottenhoff R Claessen N. Gpnmb is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease. PloS One (2016) 11(1): e0147208. 10.1371/journal.pone.0147208 26771826 PMC4714856 · DOI
  49. [60]Kramer G Wegdam W Donker-Koopman W Ottenhoff R Gaspar P Verhoek M. Elevation of Glycoprotein Nonmetastatic Melanoma Protein B in Type 1 Gaucher Disease Patients and Mouse Models. FEBS Open Bio (2016) 6(9): 902–13. 10.1002/2211-5463.12078 PMC5011488 27642553 · DOI
  50. [61]Zigdon H Savidor A Levin Y Meshcheriakova A Schiffmann R Futerman AH. Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease. PloS One (2015) 10(3): e0120194. 10.1371/journal.pone.0120194 25775479 PMC4361053 · DOI
  51. [62]Sasaki F Kumagai K Uto H Takami Y Kure T Tabu K. Expression of Glycoprotein Nonmetastatic Melanoma Protein B in Macrophages Infiltrating Injured Mucosa is Associated With the Severity of Experimental Colitis in Mice. Mol Med Rep (2015) 12(5): 7503–11. 10.3892/mmr.2015.4408 26458492 · DOI
  52. [63]Katayama A Nakatsuka A Eguchi J Murakami K Teshigawara S Kanzaki M. Beneficial Impact of Gpnmb and its Significance as a Biomarker in Nonalcoholic Steatohepatitis. Sci Rep (2015) 5: 16920. 10.1038/srep16920 26581806 PMC4652285 · DOI
  53. [64]Yang CF Lin SP Chiang CP Wu YH H’ng WS Chang CP. Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans. Am J Hum Genet (2018) 102(2): 219–32. 10.1016/j.ajhg.2017.12.012 PMC5985536 29336782 · DOI
  54. [65]Song R Lin L. Glycoprotein Nonmetastatic Melanoma Protein B (Gpnmb) Ameliorates the Inflammatory Response in Periodontal Disease. Inflammation (2019) 42(4): 1170–8. 10.1007/s10753-019-00977-4 30793225 · DOI
  55. [66]Rich JN Shi Q Hjelmeland M Cummings TJ Kuan CT Bigner DD. Bone-Related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model. J Biol Chem (2003) 278(18): 15951–7. 10.1074/jbc.M211498200 12590137 · DOI
  56. [67]Fiorentini C Bodei S Bedussi F Fragni M Bonini SA Simeone C. GPNMB/OA Protein Increases the Invasiveness of Human Metastatic Prostate Cancer Cell Lines DU145 and PC3 Through MMP-2 and MMP-9 Activity. Exp Cell Res (2014) 323(1): 100–11. 10.1016/j.yexcr.2014.02.025 24589892 · DOI
  57. [69]Mashaghi A Marmalidou A Tehrani M Grace PM Pothoulakis C Dana R. Neuropeptide Substance P and the Immune Response. Cell Mol Life Sci (2016) 73(22): 4249–64. 10.1007/s00018-016-2293-z PMC5056132 27314883 · DOI · Paper page
  58. [70]Layé S Parnet P Goujon E Dantzer R. Peripheral Administration of Lipopolysaccharide Induces the Expression of Cytokine Transcripts in the Brain and Pituitary of Mice. Brain Research. Mol Brain Res (1994) 27(1): 157–62. 10.1016/0169-328x(94)90197-x 7877446 · DOI · Paper page
  59. [71]Hagan P Poole S Bristow AF. Endotoxin-Stimulated Production of Rat Hypothalamic Interleukin-1 Beta In Vivo and In Vitro, Measured by Specific Immunoradiometric Assay. J Mol Endocrinol (1993) 11(1): 31–6. 10.1677/jme.0.0110031 8240669 · DOI
  60. [72]Banks WA Gray AM Michelle A Erickson MA Salameh TS Damodarasamy M. Lipopolysaccharide-Induced Blood-Brain Barrier Disruption: Roles of Cyclooxygenase, Oxidative Stress, Neuroinflammation, and Elements of the Neurovascular Unit. J Neuroinflamm (2015) 12: 223. 10.1186/s12974-015-0434-1 PMC4660627 26608623 · DOI · Paper page
  61. [73]Lopes PC. LPS and Neuroinflammation: A Matter of Timing. Inflammopharmacology (2016) 24(5): 291–3. 10.1007/s10787-016-0283-2 27645902 · DOI
  62. [74]Murthy MN Blauwendraat C Guelfi S Hardy J Lewis PA Trabzuni D. Increased Brain Expression of GPNMB is Associated With Genome Wide Significant Risk for Parkinson’s Disease on Chromosome 7p15.3. Neurogenetics (2017) 18: 121–33. 10.1007/s10048-017-0514-8 PMC5522530 28391543 · DOI
  63. [75]Kinoshita PF Yshii LM Orellana AMM Paixão AG Vasconcelos AR Lima LS. Alpha 2 Na +,K +-ATPase Silencing Induces Loss of Inflammatory Response and Ouabain Protection in Glial Cells. Sci Rep (2017) 7(1): 4894. 10.1038/s41598-017-05075-9 28687727 PMC5501845 · DOI
  64. [76]Orellana AM Kinoshita PF Leite JA Kawamoto EM Scavone C. Cardiotonic Steroids as Modulators of Neuroinflammation. Front Endocrinol (2016) 7: 10. 10.3389/fendo.2016.00010 PMC4754428 26909067 · DOI
  65. [77]Wu L Xiong X Wu X Ye Y Jian Z Zhi Z. Targeting Oxidative Stress and Inflammation to Prevent Ischemia-Reperfusion Injury. Front Mol Neurosci (2020) 13: 28. 10.3389/fnmol.2020.00028 32194375 PMC7066113 · DOI
  66. [78]Chung JS Dougherty I Cruz PD Jr Ariizumi K. Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation. J Immunol (2007b) 179(9): 5778–84. 10.4049/jimmunol.179.9.5778 17947650 · DOI
  67. [80]Binnewies M Roberts EW Kersten K Chan V Fearon DF Merad M. Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nat Med (2018) 24(5): 541–50. 10.1038/s41591-018-0014-x PMC5998822 29686425 · DOI · Paper page
  68. [81]Kobayashi M Chung JS Beg M Arriaga Y Verma U Courtney K. Blocking Monocytic Myeloid-Derived Suppressor Cell Function Via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells From Cancer Patients. Clin Cancer Res (2019) 25(2): 828–38. 10.1158/1078-0432.CCR-18-0330 PMC7315386 30049749 · DOI
  69. [82]Lee L Gupta M Sahasranaman S. Immune Checkpoint Inhibitors: An Introduction to the Next-Generation Cancer Immunotherapy. J Clin Pharmacol (2016) 56(2): 157–69. 10.1002/jcph.591 26183909 · DOI
  70. [83]Chung JS Ramani V Kobayashi M Fattah F Popat V Zhang S. Dc-Hil/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. Clin Cancer Res (2020) 26(6): 1449–59. 10.1158/1078-0432 31822499 · DOI
  71. [84]Woo MS Park JS Choi IY Kim WK Kim HS. Inhibition of MMP-3 or -9 Suppresses Lipopolysaccharide-Induced Expression of Proinflammatory Cytokines and iNOS in Microglia. J Neurochem (2008) 106(2): 770–80. 10.1111/j.1471-4159.2008.05430.x 18419763 · DOI

Cited by

Sorted by citations

Authors
Saade, M., Araujo de Souza, G., Scavone, C., & Kinoshita, P. F.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Kinoshita, Paula Fernanda
ORCID
Kinoshita, Paula Fernanda
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2021-05-12
Volume
12
Pages
674739-674739
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2021.674739
PMC
PMC8149902
OpenAlex
W3162634027
Cited by
216
References
10
Citations by year
2026: 45 · 2025: 45 · 2024: 54 · 2023: 45 · 2022: 24 · 2021: 3
FWCI
3.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/07896-3, 2019/05970-4, 2018/14289-6 , 2016/07427-8)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (405089/2018-0)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.125409/2016-00)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
GPNMB, neuroinflammation, inflammation, microglia, macrophages, innate immunity, neurodegenerative diseases, cancer, lipopolysaccharide, inflammation resolution
MeSH terms
Anti-Inflammatory Agents, Central Nervous System, Humans, Inflammation, Macrophages, Membrane Glycoproteins, Neoplasms, Microglia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review